Because drug development specifically against MCL1 has been considerably slower, targeting USP13 to inhibit MCL1 indirectly is likely to represent an alternative approach to potentiate the therapeutic efficacy of ABT-263 in cancer cells. This evidence concerns the gene MCL1 and cancer.